Valneva Presses Ahead With New Licensing but IXCHIQ Headwinds Overshadow Progress
Veröffentlicht: 07.07.2026 um 17:02 Uhr, Redaktion boerse-global.de
Valneva is trying to move in two directions at once. The French vaccine specialist has secured a licence for an experimental shot against enterotoxigenic E. coli (ETEC), a bacterium that causes severe diarrhoea in children across low- and middle-income countries. At the same time, its most commercially advanced product, the one-shot Chikungunya vaccine IXCHIQ, is running into fresh regulatory trouble in the United States.
The ETEC technology, developed over decades by researchers at the University of Bergen and the Norwegian research institute NORCE, targets a toxin produced by the pathogen. No licensed vaccine currently exists against ETEC, and Valneva’s newly acquired candidate is still at the preclinical stage. Laboratory studies and early clinical trials lie ahead, meaning the project will not contribute to revenue for years. For investors, the deal signals a long-term pipeline bet rather than an imminent commercial catalyst.
Far more pressing is the immediate pressure on IXCHIQ. US authorities have restricted or paused the use of the vaccine for certain defined populations, delivering a blow to what management had hoped would be a significant growth driver in 2026. The company had already cut its annual guidance back in May, citing weak sales in key travel markets. The latest regulatory curbs deepen the challenge for Valneva’s North American business.
Should investors sell immediately? Or is it worth buying Valneva?
Meanwhile, the group is undergoing a leadership overhaul. Dr. Gerd Zettlmeissl, a four-decade industry veteran, became chairman of the board of directors at the end of June, replacing Anne-Marie Graffin, who remains as vice chair. Shareholders also approved a move of the corporate headquarters to Lyon, with the Nantes site set to close. The governance changes come as Valneva grapples with a stretched balance sheet. In the first quarter of 2026, the net loss widened to €32.1 million. A capital raise in April brought in €84 million in fresh cash, offering some breathing room but underscoring the urgency of getting IXCHIQ back on track.
The stock market has taken a dim view of the combined picture. Valneva shares recently changed hands at around €2.28, giving the stock a year-to-date decline of roughly 41%. That puts the price perilously close to its 52-week low of €2.13, a level chartists warn may not hold if selling pressure intensifies. The shares trade well below their 200-day moving average, and the long-term trend lines remain decisively downward.
For now, Valneva is asking investors to juggle two very different timelines: the distant promise of an ETEC vaccine and the painful near-term reality of a constrained US franchise. Patience may be essential, but the stock’s technical condition suggests that patience is already wearing thin.
Ad
Valneva Stock: New Analysis - 7 July
Fresh Valneva information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
